ARTICLE | Company News
CHMP recommends Amgen's biosimilar Avastin
November 10, 2017 7:58 PM UTC
EMA's CHMP recommended approval of ABP 215 from Amgen Inc. (NASDAQ:AMGN), a biosimilar of Avastin bevacizumab, for all cancer types on Avastin's EU label: non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and colorectal, breast, ovarian and cervical cancers.
Amgen said CHMP's recommendation is the committee's first for a biosimilar of Avastin...
BCIQ Target Profiles